Developing effective countermeasures against a diverse array of viral and toxin threats requires precise, reliable, and safe functional assessment tools. Creative Biolabs' Virus & Toxin Neutralization Assessment Services provide a versatile suite of gold-standard and advanced in vitro assays to quantify the inhibitory potency of your therapeutic candidates. We deliver robust, quantitative data, from high-throughput screening to critical safety profiling, all within compliant biosafety frameworks, empowering your research and development with confidence from discovery to regulatory submission.
Virus and Toxin Neutralization is a fundamental bioassay that evaluates the functional capacity of antibodies or other agents to inhibit the infectivity of a pathogenic virus or the biological activity of a toxin. To address the safety constraints of handling live, highly pathogenic agents like SARS-CoV-2 or MERS-CoV, pseudovirus-based neutralization assays have become a preferred, high-throughput method that operates under standard Biosafety Level-2 conditions while correlating strongly with traditional live-virus tests. Virus & Toxin neutralization assessment is therefore pivotal for characterizing immune responses in convalescent or vaccinated individuals, screening and qualifying therapeutic monoclonal antibodies and entry inhibitors, supporting critical vaccine immunogenicity studies, and informing public health strategies.
Fig.1 Assessing antibody-mediated neutralization against pathogenic coronaviruses. 1
Creative Biolabs' Virus & Toxin Neutralization Assessment Services offer a comprehensive suite of cell-based neutralization assays, spanning gold-standard viral inhibition, functional toxin neutralization, and critical safety evaluations for antibody therapies.
Our comprehensive viral neutralization services provide quantitative, functional analysis of agents that prevent live virus infection.
Our toxin neutralization platforms evaluate the protective efficacy of antitoxins and inhibitors against the cytotoxic effects of bacterial and venom toxins.
This critical safety service identifies the potential for antibodies to exacerbate viral infection, a key risk factor in therapeutic and vaccine development. This assay utilizes Fc receptor-expressing cell lines to specifically test for antibody-mediated enhancement of infection, an essential de-risking step for candidates targeting ADE-prone viruses.
Our suite of advanced neutralization services delivers critical, cell-based insights to de-risk and accelerate the development of antiviral and antitoxin therapeutics, vaccines, and biologics from early discovery through regulatory submission.
This service quantifies the functional ability of biological agents, such as monoclonal antibodies or therapeutics, to block viral infection of host cells. Directly measuring the neutralization of live virus infectivity provides critical data for applications in vaccine efficacy testing, antiviral drug discovery, and the selection of potent antibodies for therapeutic development.
This module determines the effectiveness of candidate antitoxins or neutralizing antibodies in counteracting the cytotoxic effects of potent bacterial or venom toxins. It is a vital tool for the preclinical development and potency verification of lifesaving antitoxins, as well as for the safety assessment of neutralizing products intended for clinical use.
This specialized safety assessment evaluates the potential for therapeutic antibodies or vaccine-elicited immune sera to inadvertently enhance viral infection through Fc receptor-mediated uptake. Identifying this risk is crucial for the safe development of biologics and vaccines against viruses known for ADE.
As a gold-standard benchmark for neutralization, the PRNT assay provides definitive, quantitative titers of neutralizing antibodies. Its high reproducibility and precision make it indispensable for critical applications, including regulatory filings, clinical trial-enabling studies, and the precise characterization of protective immune responses.
Required starting materials:
Key Steps
Final Deliverables
At Creative Biolabs, we provide more than just standard assays; we deliver critical insights through scientifically advanced methodologies designed to solve your most challenging development hurdles. Our high-sensitivity, low-virus-input protocols enable the reliable detection of subtle yet potent neutralizing activities that conventional methods may miss. Partner with us to de-risk your candidates with data that is both highly accurate and translationally relevant.
To request a detailed quote or discuss your project requirements, please . We are ready to collaborate on advancing your therapeutic candidates.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.